Clinical trials: Tumor Pancreas
Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor
Pancreatic Fistula After Minimally Invasive Enucleation
Patients suffering from postoperative pancreatic fistula (POPF) after minimally invasive enucleation (MIEN) show a characteristic pattern of longer duration and milder symptoms, which is different from pancreatic fistula after…
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas
- Trial name
- NCT06557408
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Fudan University
Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic…
- Conditions
- Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic
- Trial name
- NCT03984214
- Testing
- Dronabinol in Oral Dosage Form
- Where
- 11 sites in Austria, Germany
- Volunteers
- 109 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Gastrointestinal Cancer, Liver Cancer
Collecting Solid Tumor Tissue to Identify New Treatments
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells…
- Conditions
- Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
- Trial name
- NCT01658917
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01222689
- Testing
- erlotinib hydrochloride, selumetinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
No Standard therapy has been approved for third-line therapy of advanced pancreatic cancer. K001 is peptidoglycan prepared from the marine microorganism, with an anti-tumor activity.
- Trial name
- NCT04183478
- Testing
- K-001
- Where
- China
- Volunteers
- 600 people
- Sponsor
- RenJi Hospital
Pancreatic Cancer
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Patients with PCLM account for the majority of our department's pancreatic cancer cases and often have limited surgical options due to the aggressive nature of their tumors.
- Trial name
- NCT06404840
- Testing
- nimotuzumab, AG chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Pancreatic Cancer
Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection
Recurrence of Pancreatic Cancer(PCa) is a multifactorial event. Based on the clinicopathological characteristics and imaging data of patients with PCa, the investigators used image processing and machine learning algorithms to…
- Trial name
- PaC (NCT05589480)
- Testing
- preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Luo Cong
Pancreatic Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00025168
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride, radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor…
- Trial name
- NCT02648282
- Testing
- Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma
PDAC Peripheral and Portal Vein Sampling
This is a research study in which bio-specimens (whole blood, plasma and serum from peripheral circulation and portal vein) will be collected from patients with pancreatic adenocarcinoma for translational research.
- Trial name
- NCT04289961
- Testing
- Portal vein sampling
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- The Christie NHS Foundation Trust
Pancreatic Neoplasm
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy.
- Trial name
- NCT00711191
- Testing
- monoclonal antibody, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic…
- Trial name
- MAESTRO (NCT01746979)
- Testing
- TH-302, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 693 people
- Sponsor
- ImmunoGenesis
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Pancreatic Cancer
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
This study compare the efficacy of Astragalus combined with Gemcitabine to Gemcitabine alone as neoadjuvant treatment for pancreatic cancer.
- Trial name
- NCT06234072
- Testing
- Astragalus + Gemcitabine, Gemcitabine alone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen University General Hospital
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and ß-catenin.
- Conditions
- Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT01764477
- Testing
- PRI-724
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Prism Pharma Co., Ltd.
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
- Trial name
- NCT03906357
- Testing
- Pemigatinib
- Sponsor
- Incyte Corporation
Pancreatic Cancer
Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions
This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made.
- Trial name
- NCT01809028
- Testing
- EUS FNA with 2 passes, EUS FNA with 4 passes
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- AdventHealth
Pancreatic Adenocarcinoma
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
The research trial is testing the experimental treatment MSC1936369B in combination with Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT01016483
- Testing
- Pimasertib, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 141 people
- Sponsor
- EMD Serono
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.